Sino Biopharmaceutical (HKG:1177) presented preliminary data from its first-in-human Phase I clinical study of cancer drug TQB2102 at the 2025 ASCO Annual Meeting, according to a Tuesday filing with the Hong Kong Exchange.
The company reported encouraging results, with response rates of up to 70% in certain HER2-positive cancers, including breast and gastric cancers -- even among patients who had not responded to prior treatments.
Side effects were described as manageable, with only a few cases of serious lung-related adverse events.
TQB2102 is currently in Phase 3 trials and, if successful, could become the world's first approved bispecific HER2 antibody-drug conjugate (ADC), the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。